Tert-butyl 3-[5-(chloroamino)-4-ethylpyridin-2-yl]azetidine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: Tert-butyl 3-[5-(chloroamino)-4-ethylpyridin-2-yl]azetidine-1-carboxylate
• 英文别名: tert-butyl 3-[5-(chloroamino)-4-ethylpyridin-2-yl]azetidine-1-carboxylate
• 化学式: C₁₅H₂₂ClN₃O₂
• 分子量: 311.81
• InChiKey: NCQADEHAZVBWAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
  申请人：GALAPAGOS NV

  公开号：US20140213576A1

  公开（公告）日：2014-07-31

  A novel compound according to Formula I, able to inhibit JAK as disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

  一种新的化合物按照公式I，能够抑制JAK，该化合物可以制备为药物组合物，并可用于哺乳动物包括人类的预防和治疗多种疾病，例如过敏或炎症性疾病、自身免疫疾病、增生性疾病、移植排斥、涉及软骨周转障碍的疾病、先天性软骨畸形和/或与IL6或干扰素的高分泌相关的疾病，举例而言。
• [EN] NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES<br/>[FR] NOUVEAU COMPOSÉ UTILISÉ POUR TRAITER LES MALADIES DÉGÉNÉRATIVES ET INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2014111380A1

  公开（公告）日：2014-07-24

  A novel compound according to Formula I, able to inhibit JAK as disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.